IP Library Granted Patent US 9,161,914
Granted Patent B2
US 9,161,914 · App. 14/297,293 · Granted Oct 20, 2015

Topical compositions and methods for making and using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,161,914
App. No.
14/297,293
Granted
Oct 20, 2015
Kind
B2
Abstract

The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.

Claims (29)

1. A method of treating a fungal infection in a patient in need thereof, comprising administering to the patient a gel composition consisting essentially of:

(i) naftifine or a pharmaceutically acceptable salt thereof, present in an amount of from about 0.5 wt % to about 4 wt %;

(ii) a first solvent which is a glycol solvent, present in an amount of from about 10 wt % to about 25 wt %;

(iii) a second solvent which is an alkyl alcohol solvent, present in an amount of from about 10 wt % to about 25 wt %;

(iv) a non-carbomer rheology modifier selected from a hydroxy cellulose, present in an amount of from about 0.75 wt % to about 2.25 wt %;

(v) a polysorbate solubilizing agent present in an amount of from about 3 wt % to about 8 wt %;

(vi) a pH adjuster selected from an amine base; and

optionally one or more of: water, a preservative, a chelating agent, a coloring agent, and a fragrance,

wherein the gel composition has a pH of about 4.5 to about 6.0.

2. The method according to claim 1 , wherein the fungal infection is a superficial fungal infection of the skin.

3. The method according to claim 2 , wherein the superficial fungal infection of the skin is selected from Tinea cruris, Tinea corporis, interdigital Tinea pedis, moccasin-type Tinea pedis, Tinea manuum, Tinea versicolor (pityriasis), Tinea nigra, cutaneous candidiasis, Tinea faciei, and white and black piedra.

4. The method according to claim 3 , wherein the superficial fungal infection of the skin is selected from interdigital Tinea pedis.

5. The method according to claim 4 , wherein the interdigital Tinea pedis is caused by Epidermophyton floccosum, Trichophyton mentagrophytes , or Trichophyton rubrum .

6. The method according to claim 1 , wherein the naftifine or a pharmaceutically acceptable salt thereof is present in an amount of from about 1.0 wt % to about 3.0 wt %.

7. The method according to claim 1 , wherein the glycol solvent is present in an amount of about 18 wt % to about 22 wt %.

8. The method according to claim 7 , wherein the glycol solvent is propylene glycol.

9. The method according to claim 1 , wherein the alkyl alcohol is present in an amount of from about 17 wt % to about 22 wt %.

10. The method according to claim 9 , wherein the alkyl alcohol is ethanol.

11. The method according to claim 1 , wherein the hydroxy cellulose is hydroxyethyl cellulose.

12. The method according to claim 1 , wherein the polysorbate solubilizing agent is Polysorbate 20.

13. The method according to claim 1 , wherein the polysorbate solubilizing agent is Polysorbate 80.

14. The method according to claim 1 , wherein the naftifine, or pharmaceutically acceptable salt thereof, is naftifine hydrochloride.

15. The method according to claim 1 , wherein the naftifine, or a pharmaceutically acceptable salt thereof, is present in an amount of about 2.0 wt %, the glycol solvent is present in an amount of about 20 wt %, the alkyl alcohol solvent is present in an amount of about 19 wt %, the non-carbomer rheology modifier is present in an amount of about 1.75 wt %, and the polysorbate solubilizing agent is present in an amount of about 5 wt %.

16. The method according to claim 15 , wherein the glycol solvent is propylene glycol.

17. The gel composition of claim 15 , wherein the alcohol solvent is ethanol.

18. The gel composition of claim 15 , wherein the non-carbomer rheology modifier is hydroxyethyl cellulose.

19. The method according to claim 15 , wherein the polysorbate solubilizing agent is Polysorbate 20 or Polysorbate 80.

20. The method according to claim 15 , wherein the naftifine or pharmaceutically acceptable salt thereof is naftifine hydrochloride.

21. The method according to claim 1 , consisting essentially of 2.0 wt % naftifine hydrochloride, about 20 wt % propylene glycol, about 19 wt % ethanol, about 5 wt % Polysorbate 20, about 1.75 wt % hydroxyethyl cellulose, about 1.0 wt % benzyl alcohol, about 0.17 wt % trolamine, about 0.02 wt % ethylenediaminetetracetic acid or a salt thereof, water, and optionally one or more of a coloring agent and a fragrance.

Assignments (8)
SECURITY INTEREST Recorded Mar 23, 2026
From: LEGACY PHARMA INC. SEZC
To: ROOSTER LP
Reel/Frame 074151/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2025
From: SEBELA IRELAND LIMITED
To: LEGACY PHARMA INC.
Reel/Frame 070028/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2019
From: SEBELA INTERNATIONAL BERMUDA LIMITED
To: SEBELA IRELAND LIMITED
Reel/Frame 049791/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2018
From: SEBELA INTERNATIONAL LIMITED
To: SEBELA INTERNATIONAL BERMUDA LIMITED
Reel/Frame 046200/0934 →
RELEASE OF SECURITY INTEREST Recorded May 18, 2018
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENT
To: SEBELA INTERNATIONAL LIMITED
Reel/Frame 047506/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2016
From: MERZ PHARMACEUTICALS, LLC
To: SEBELA INTERNATIONAL LIMITED
Reel/Frame 040411/0407 →
SECURITY INTEREST Recorded Nov 21, 2016
From: SEBELA INTERNATIONAL LIMITED
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 040394/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2015
From: HARDAS, BHUSHAN; DALTON, DONNA
To: MERZ PHARMACEUTICALS, LLC
Reel/Frame 035147/0687 →